CA
NZ
UK
AU
IND
US
A statement of changes in beneficial ownership filed on September 18, 2026, disclosed that Thomas Fuchs, a director of GeneDx Holdings Corp., acquired 1,146 shares of Class A Common Stock through the settlement of restricted stock units on September 17, 2026.
GeneDx Holdings Corp. Chief Financial Officer Kevin Feeley filed a Form 4 on September 18, 2026, reporting the vesting of restricted stock units and a related "sell to cover" transaction in Class A Common Stock on September 16, 2026.
GeneDx Holdings Corp. Chief Executive Officer Katherine Stueland filed a Form 4 on September 18, 2026, reporting the vesting of restricted stock units and related tax-withholding share sales that occurred on September 16, 2026.
Scott R. Lovett, President, Go to Market at Fastly, Inc. (NASDAQ:FSLY), filed a Form 4 on September 18, 2026, reporting the sale of 34,820 shares of Class A Common Stock on September 16, 2026, to satisfy tax obligations arising from the vesting of previously …
Jeffrey Ford, Principal Accounting Officer of Fastly, Inc., filed a Form 4 on September 18, 2026, reporting the sale of 37,091 shares of Class A Common Stock on September 16, 2026, to satisfy tax obligations related to vesting restricted stock units.
A Form 4 filed on September 18, 2026, by Anastasios Margaronis, a director of Diana Shipping Inc. (NYSE:DSX), discloses the exercise of 122,471 warrants by his spouse through an affiliated entity on September 17, 2026.
A Form 4 filed on September 18, 2026 discloses that Eleftherios Papatrifon, a director of Diana Shipping Inc. (NYSE:DSX), sold 20,000 warrants on September 16 and 17, 2026 at an exercise price of $1.69527.
Kristopher Hanson, General Counsel of MapLight Therapeutics, Inc. (NASDAQ:MPLT), filed a Form 4 on September 18, 2026, disclosing the sale of 16,509 shares of Voting Common Stock on September 16, 2026, pursuant to a pre-established Rule 10b5-1 trading plan.
Christopher Ryan Sullivan, Chief Financial Officer of Avalo Therapeutics, Inc. (NASDAQ:AVTX), filed a Form 4 on September 18, 2026, disclosing an option exercise and sale of common stock on September 16, 2026, executed under a pre-established Rule 10b5-1 trading plan.
Masaru Matsuda, Executive Vice President and Chief Legal Officer of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), filed a Form 4 on September 18, 2026, reporting the sale of 3,674 shares of common stock on September 16, 2026.
Please wait processing your request...